Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years.
Nick Paul Taylor
Oct 29, 2024 6:16am
Sponsored
Discover Turbine’s way to build avatars true to patient biology
Oct 28, 2024 8:00am
GSK aims to extend lupus dominance via $300M T-cell engager deal
Oct 29, 2024 8:00am
Sponsored
2024 Executive Interviews at Fierce Biotech Summit and New Product Planning
Oct 28, 2024 8:00am
Neurocrine, Idorsia part ways 2 years after double phase 2 fails
Oct 29, 2024 7:15am
Gene therapy reduces harmful protein levels in mouse kidneys
Oct 29, 2024 12:54pm
Medtech News
TCT: Abbott atherectomy study fails vs. balloon angioplasty
Oct 29, 2024 12:30pm
TCT: Using TAVR early helps prevent later hospitalizations
Oct 28, 2024 11:22am
Dexcom posts mixed-bag earnings report amid Stelo rollout
Oct 25, 2024 1:30pm
FDA approves Medtronic's Affera 2-in-1 afib ablation system
Oct 25, 2024 12:00pm
See More Medtech News